Evidence map›Paper›PMID 39789479›Full record

ArticleBMC cancer2025

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial.

Graham McIlroy, Charlotte Gaskell, Aimee Jackson, Emily Yafai, Rachel Tasker, Catherine Thomas, Sonia Fox, Rebecca Boucher, Fitsum Ghebretinsea, Claire Harrison and 2 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Graham McIlroyCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. g.w.mcilroy.1@bham.ac.uk.
Charlotte GaskellCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Aimee JacksonCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Emily YafaiCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Rachel TaskerCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Catherine ThomasCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Sonia FoxCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Rebecca BoucherCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Fitsum GhebretinseaCancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
Claire HarrisonDepartment of Clinical Haematology, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London, UK.
Adam J MeadMedical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR, Biomedical Research Centre, University of Oxford, Oxford, UK.
Mary Frances McMullinCentre for Medical Education, Queen's University Belfast, Belfast City Hospital, Lisburn Road, Belfast, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyelofibrosis (MF) is a clonal haematopoietic disease, with median overall survival for patients with primary MF only 6.5 years. The most frequent gene mutation found in patients is JAK2

methodsFEDORA is a single arm, multicentre, open-label, Bayesian phase II trial to assess tolerability, safety, and activity of fedratinib with ropeginterferon alfa-2b aiming to recruit 30 patients. Patients with JAK2 DISCUSSION: FEDORA is using a Bayesian trial design and aims to provide evidence of the tolerability, safety, and activity of combining fedratinib with ropeginterferon alfa-2b upon which the decision as to whether a phase III trial is warranted will be based.

trial registrationEudraCT number: 2021-004056-42. ISRCTN: 88,102,629.

Indexed as

Clinical Trials, Phase II as TopicInterferon-alphaInterferon alpha-2Multicenter Studies as TopicPolyethylene GlycolsPrimary MyelofibrosisPyrrolidinesAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBayes TheoremBenzenesulfonamidesFemaleHumansJanus Kinase 2MaleBenzenesulfonamidesfedratinibInterferon-alphaInterferon alpha-2JAK2 protein, humanJanus Kinase 2peginterferon alfa-2bPolyethylene GlycolsPyrrolidinesRecombinant ProteinsSulfonamidesBayesian designClinical trialFedratinibJAK2 inhibitionMyelofibrosisPhase IIRopeginterferon alfa-2bTolerability

Identifiers

PMID39789479
PMCPMC11720754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.